Losigamone manufacturers
- Losigamone
-
- $75.00
-
2026-07-15
- CAS:112856-44-7
- Purity: 99.98%
- Supply Ability: 10g
|
| | Losigamone Basic information |
| Product Name: | Losigamone | | Synonyms: | Losigamone;losigame;5-[(2-Chlorophenyl)hydroxymethyl]-4-methoxyfuran-2(5H)-one;Losigamon;2(5H)-Furanone, 5-[(R)-(2-chlorophenyl)hydroxymethyl]-4-methoxy-, (5S)-rel-;ADD 137022;ADD137022;ADD-137022 | | CAS: | 112856-44-7 | | MF: | C12H11ClO4 | | MW: | 254.67 | | EINECS: | | | Product Categories: | | | Mol File: | 112856-44-7.mol |  |
| | Losigamone Chemical Properties |
| Boiling point | 480.1±45.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | pka | 12.32±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | Losigamone Usage And Synthesis |
| Uses | Losigamone (AO-33) is an orally active antiepileptic compound. Losigamone blocks sodium channel. Losigamone stimulates the neuronal chloride channel and enhance chloride influx. Losigamone potentiates GABA-mediated responses and reduces epileptiform activity induced by chloride channel antagonists. Losigamone can be used for epilepsy research[1][2]. | | References | [1] Chen H, et al. Losigamone add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD009324. DOI:10.1002/14651858.CD009324.pub5
[2] Jones FA, et al. The anticonvulsant effects of the enantiomers of losigamone. Br J Pharmacol. 1999 Nov;128(6):1223-8. DOI:10.1038/sj.bjp.0702919 |
| | Losigamone Preparation Products And Raw materials |
|